Qtern FDA Approval History
Qtern (dapagliflozin and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor fixed-dose combination for the treatment of adult patients with type 2 diabetes.
Development Timeline for Qtern
|Feb 28, 2017||FDA Approves Once-Daily Qtern (dapagliflozin and saxagliptin) Tablets for Adults with Type-2 Diabetes|
|Oct 16, 2015||AstraZeneca Receives Complete Response Letter for Saxagliptin/Dapagliflozin Fixed-Dose-Combination|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.